Highlights

  • CSL Limited confirmed its Horizon 2 plasma processing technology will move into human Clinical Trials targeted for mid-2027.
  • The technology is designed to increase immunoglobulin output from existing plasma volumes through improved Manufacturing efficiency.
  • Trial material will be produced at CSL's Broadmeadows Facility in Victoria following consultations with the U.S. FDA and European Medicines Agency.
  • CSL reported H1'FY2026 Revenue of US$8.3 billion and underlying NPATA of US$1.9 billion.

CSL Limited (ASX:CSL) has confirmed it will progress its next-generation plasma processing technology, known as Horizon 2, into human clinical trials as the company seeks to improve immunoglobulin production efficiency from donated plasma.

The announcement, released to the ASX on 29 July 2026, represents a manufacturing development milestone for CSL's plasma therapies business. The technology is designed to extract more immunoglobulin from the same Volume of plasma compared with existing fractionation processes.

For CSL (ASX:CSL), a company whose plasma-derived therapies division remains a major contributor to group operations, improving manufacturing Yield could provide an additional pathway to increase Supply capacity without relying solely on higher plasma collection volumes.

What Was Announced?

CSL announced that it will commence clinical trials to evaluate immunoglobulin produced using Horizon 2, a patented manufacturing process designed to improve immunoglobulin yield from source plasma.

Immunoglobulin is a plasma-derived protein used in treatments for immune deficiencies, autoimmune conditions and neurological disorders. As one of CSL's key product categories, improving production efficiency could allow the company to generate more finished product from existing plasma resources.

Clinical trial material will be manufactured at CSL's Broadmeadows facility in Victoria. The company has completed consultations with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) ahead of the planned trial program.

CSL expects trials to begin around mid-2027 but has not disclosed specific details regarding trial size, duration, expected yield improvement percentage or final regulatory timelines.

Why This Matters

For CSL (ASX:CSL), Horizon 2 represents a potential manufacturing efficiency opportunity within its CSL Behring plasma therapies division.

Rather than relying only on additional plasma collection centres or manufacturing expansion, a validated improvement in production yield could allow CSL to increase immunoglobulin output from existing infrastructure.

The initiative is being developed alongside the company's broader Investment in plasma manufacturing capacity, including expansion activities at its Kankakee facility in Illinois.

However, Horizon 2 remains a clinical and regulatory development program rather than a commercial product launch. The technology must complete trials and receive regulatory approval before any commercial application.

Company Background

CSL Limited is a global biotechnology company operating across three main divisions: CSL Behring, CSL Seqirus and CSL Vifor.

CSL Behring is the company's largest Business segment, focused on plasma-derived therapies including immunoglobulin, albumin and haemophilia treatments. Products such as Privigen and Hizentra are key parts of the immunoglobulin portfolio.

CSL operates plasma collection centres and manufacturing facilities across multiple regions, including Australia and the United States.

The company's strategy includes expanding plasma supply, improving manufacturing efficiency and developing therapies across immunology, vaccines and specialty healthcare areas.

Financial Position

CSL reported H1'FY2026 total revenue of US$8.3 billion, down 4% at constant currency, with underlying net profit after tax, adjusted (NPATA) of US$1.9 billion, down 7%.

Reported statutory net profit declined by approximately 81% at constant currency, reflecting one-off items including restructuring costs.

Within CSL Behring, revenue was US$5.5 billion, down 7%, while immunoglobulin revenue was US$3.0 billion, down 6%. Albumin revenue declined 27%, partly influenced by policy changes in China.

Cash flow from operations increased 3% to US$1.3 billion.

CSL maintained full-year FY2026 guidance of approximately 2–3% revenue growth and 4–7% NPATA growth at constant currency, excluding restructuring and Impairment costs.

What Comes Next?

The next major milestone for CSL (ASX:CSL) is the planned commencement of Horizon 2 clinical trials around mid-2027.

Investors will be watching for further details on trial design, participant numbers, regulatory discussions and potential timelines for future commercial use.

CSL's FY2026 full-year results will also provide further updates on operational performance, including progress across the CSL Behring division and broader company guidance.

Risks

Horizon 2 remains subject to clinical and regulatory execution risks, including the possibility of additional data requirements or timeline changes. The mid-2027 trial timeframe remains an expectation rather than a confirmed commercial milestone. CSL's plasma therapies business continues to face pricing pressure, competitive dynamics and policy-related risks affecting products such as immunoglobulin and albumin. Currency movements, plasma collection costs and healthcare funding conditions may also influence Earnings independently of Horizon 2.

Investor Takeaway

CSL's Horizon 2 announcement provides visibility around a potential manufacturing efficiency initiative aimed at increasing immunoglobulin output from existing plasma volumes.

For CSL (ASX:CSL), the technology could become a longer-term operational lever if clinical trials and regulatory reviews are completed successfully. However, the program remains in development, with trials not expected to begin until mid-2027 and no confirmed approval timeline.

The impact of Horizon 2 will need to be assessed alongside CSL's broader plasma therapies performance, FY2026 guidance delivery and ongoing operational initiatives.